InterveXion Therapeutics
Little Rock
About InterveXion Therapeutics
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $52.8M
- Last round: Grant (Nov 2021)
- Website: intervexion.com
- Phone: 501.554.2377
Industries & Categories
Addiction Treatment, Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/intervexion-therapeutics-74617 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.